=== PAGE 1 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the text content extracted from the PDF page, preserving its original layout and structure:

(Header Area)
                 NASCENT                                                    Products Investors News About Contact
                 BIOTECH, INC.

Pritumumab
targets a novel antigenic on
cancer cells

Delivering human antibodies for the treatment of cancer

(Visual Element Description):
On the right side of the main header, there is an image depicting a three-dimensional molecular structure, likely representing an antibody or a similar protein. It is shaped like a 'Y' and is composed of numerous small, colored spheres or dots, forming distinct segments. The segments are colored green, light blue, dark blue, and purple, indicating different parts of the molecule. This image serves to visually represent the biological or molecular nature of the company's product, Pritumumab, which is described as targeting cancer cells using human antibodies.

(Main Content Area - Left Column)               (Main Content Area - Right Column)
Pritumumab                                      Latest News

Learn more about Nascent Biotech's primary drug product,         JUNE 3, 2019
Pritumumab.                                     Nascent CEO Sean Carrick On RedChip Money Report

NBIO Stock Information                          MARCH 10, 2019
                                                Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and
NBIO: (%)                                       promises

Investor Presentation                           DECEMBER 11, 2018
                                                Nascent Biotech Receives Clearance from FDA to Begin Phase I Human
Download Investor Presentation                  Trials in Brain Cancer

Email Updates                                   JULY 27, 2018
                                                Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic
Subscribe Now                                   antibodies toward the paratope of malignant associated autologous anti-
                                                vimentin antibody, CLN-IgG (Pritumumab)

                                                APRIL 4, 2018
                                                Nascent Biotech to Sponsor Human Antibodies & Hybridomas
                                                Conference

(Footer)
Copyright Nascent Biotech. All rights reserved.
